佛慈制药(002644) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was CNY 307,394,758.83, representing a 29.77% increase compared to CNY 236,878,872.61 in the same period last year[5] - Net profit attributable to shareholders was CNY 27,454,528.98, up 27.72% from CNY 21,496,460.61 year-on-year[5] - The net profit after deducting non-recurring gains and losses was CNY 23,201,984.94, reflecting a 29.17% increase from CNY 17,962,206.37 in the previous year[5] - Total operating revenue for Q1 2023 reached CNY 307,394,758.83, a 29.7% increase from CNY 236,878,872.61 in the same period last year[22] - Net profit for Q1 2023 was CNY 27,436,028.66, representing a 27.5% increase compared to CNY 21,545,308.08 in Q1 2022[23] - The total comprehensive income attributable to the parent company was CNY 27,454,528.98, compared to CNY 21,496,460.61 in the previous period, representing an increase of approximately 27.9%[24] Assets and Liabilities - The company's total assets increased by 4.67% to CNY 2,707,397,143.84 from CNY 2,586,568,848.41 at the end of the previous year[5] - Total liabilities increased to CNY 945,487,854.39, up from CNY 852,595,587.62 year-on-year[20] - The equity attributable to shareholders of the parent company rose to CNY 1,742,844,242.35, compared to CNY 1,715,389,713.37 in the previous year[20] - The company reported a total current asset of 1,416,547,234.24 RMB, an increase from 1,291,068,156.43 RMB at the beginning of the year, representing an increase of approximately 9.8%[18] Cash Flow - The net cash flow from operating activities was negative at CNY -6,151,682.38, a decrease of 122.99% compared to CNY 26,757,794.43 in the same period last year[8] - Cash inflow from operating activities totaled CNY 281,429,158.62, up from CNY 198,038,162.63, marking a rise of about 42.0%[26] - Cash outflow from operating activities was CNY 287,580,841.00, compared to CNY 171,280,368.20 in the previous period, resulting in a net cash flow from operating activities of -CNY 6,151,682.38[26] - Investment activities resulted in a cash outflow of CNY 15,583,185.26, significantly higher than CNY 1,395,928.90 in the previous period, leading to a net cash flow from investment activities of -CNY 13,583,185.26[27] - Cash inflow from financing activities was CNY 500,000.00, while cash outflow was CNY 14,049,700.00, resulting in a net cash flow from financing activities of -CNY 13,549,700.00[27] - The ending balance of cash and cash equivalents decreased to CNY 354,400,479.61 from CNY 384,067,722.30, a decline of approximately 7.7%[27] Shareholder Information - The total number of common shareholders at the end of the reporting period is 31,467[11] - The largest shareholder, Lanzhou Foci Pharmaceutical Industry Development Group, holds 61.63% of the shares, totaling 314,713,676 shares, with 150,000,000 shares pledged[11] - The company reported that the pledge of shares by the controlling shareholder accounts for 29.37% of the total share capital[13] Research and Development - Research and development expenses increased by 56.47% to CNY 6,296,817.19, up from CNY 4,024,334.17 year-on-year, indicating a focus on enhancing research collaboration[7] - Research and development expenses increased to CNY 6,296,817.19, up 56.5% from CNY 4,024,334.17 in the previous year[22] - The company plans to continue focusing on R&D and market expansion strategies to drive future growth[22] Management and Operational Costs - The company's management expenses rose by 59.44% to CNY 20,733,888.20, attributed to increased depreciation costs[7] - Total operating costs amounted to CNY 281,431,478.22, up 33% from CNY 211,498,791.15 year-on-year[22] Changes in Control - The controlling shareholder, Lanzhou Foci Pharmaceutical Industry Development Group, is undergoing a change in actual control, with Gansu State-owned Assets Investment Group intending to acquire 100% of its equity[14] - Gansu State-owned Assets Investment Group will indirectly hold 61.63% of the company's issued shares post-acquisition, triggering a mandatory tender offer for the remaining shares[15] - The tender offer price is set at 9.60 RMB per share, covering 195,943,324 shares, which is 38.37% of the company's issued shares[15] - The company is actively progressing with the necessary audits and approvals for the change in control, which carries certain uncertainties[16] Other Information - The company reported a government subsidy of CNY 5,059,784.65, contributing to its non-recurring gains[6] - The company reported an investment income of CNY 612,806.12, indicating a positive contribution from investments[23] - The company did not undergo an audit for the first quarter report[28] - The report was presented by the board of directors on April 25, 2023[29]